Activity Description
The goal of the GVHD Interactive Provider Network ECHO Program is to connect GVHD specialists with community providers to share expertise, discuss cases and improve patient care.
The network is based on the ECHO Model™ (Extension for Community Healthcare Outcomes) which uses proven adult learning techniques and interactive video technology to connect community providers with specialists in collaborative sessions.
The sessions, designed around case-based learning and mentorship, will help primary care and community-based practitioners gain the practical expertise required to care for GVHD patients. Questions and comments from the learners will be encouraged to facilitate discussion.
Speakers
Steve Pavletic, MD, MS
Senior Clinician Head, Graft-Versus-Host Disease and Late Effects Section Immune Deficiency Cellular Therapy Program, National Cancer Institute, Bethesda, MD
Steve Pavletic, MD, MS, has no relevant financial relationships with ineligible companies to disclose for this educational activity.
Kirk Schultz, MD, FCAHS
Professor of Pediatrics
University of British Columbia
BC Childrens Hospital and Research Institute
Vancouver, BC
Kirk Schultz, MD, FCAHS, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant for: AlloVir, Bristol Myers Squibb/Juno, Elysium, Incyte, Janssen, Jazz, Novartis, Sanofi, Seres
Geoffrey Cuvelier, MD, FRCPC
Director, Pediatric Blood and Marrow Transplant, Cancer Care Manitoba
Associate Professor, University of Manitoba
Winnipeg, CA
Geoffrey Cuvelier, MD, FRCPC, has a financial interest/relationship or affiliation in the form of:
The following relationships have ended within the last 24 months:
Advisory Board/Consultant for: Miltenyi Biotec
Iskra Pusic, MD
Associate Professor
Washington University St. Louis
St. Louis, MO
Iskra Pusic, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant for: Incyte
The following relationships have ended within the last 24 months:
Advisory Board/Consultant for: Syndax
Accreditation and Disclosure Information
Target Audience
This CE activity is intended for physicians of all specialties, nurse practitioners, physician assistants, and other healthcare professionals who treat patients with chronic GVHD.
Educational Objectives
After completing this CE activity, the participant should be better able to:
- Explain how chronic GvHD can present with atypical manifestations in organ systems not classically described by the NIH consensus criteria.
- Discuss what is known (and what is not known) about chronic GvHD involving the hematopoietic system, peripheral and central nervous system, kidneys, MSK, and serosal membranes.
- Review how to integrate the assessment of atypical chronic GVHD into patient care, including some of the limitations in doing so.
Program Agenda
- Welcome and Introductions – Kirk Schultz, MD, FCAHS
- Didactic presentation – Geoffrey Cuvelier, MD, FRCPC
- Case presentation – Iskra Pusic, MD
- Q & A and Panel Discussion
- Closing Announcements
Accreditation, Support and Credit
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc., and Aplastic Anemia and MDS International Foundation. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Support Statement
This CE activity is supported by an educational grant from Incyte Corporation.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and 1.0 contact hour in the area of pharmacology.
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.
Disclosure & Conflict of Interest Policy
Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
Faculty Disclosures
Chair/Planner
Steve Pavletic, MD, MS
Senior Clinician
Head, Graft-Versus-Host Disease and Late Effects Section
Immune Deficiency Cellular Therapy Program
National Cancer Institute
Bethesda, MD
Steve Pavletic, MD, MS, has no relevant financial relationships with ineligible companies to disclose for this educational activity.
Planner/Moderator
Kirk Schultz, MD, FCAHS
Professor of Pediatrics
University of British Columbia
BC Childrens Hospital and Research Institute
Vancouver, BC
Kirk Schultz, MD, FCAHS, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant for: AlloVir, Bristol Myers Squibb/Juno, Elysium, Incyte, Janssen, Jazz, Novartis, Sanofi, Seres
Planner/Presenter
Geoffrey Cuvelier, MD, FRCPC
Director, Pediatric Blood and Marrow Transplant, Cancer Care Manitoba
Associate Professor, University of Manitoba
Winnipeg, CA
Geoffrey Cuvelier, MD, FRCPC, has a financial interest/relationship or affiliation in the form of:
The following relationships have ended within the last 24 months:
Advisory Board/Consultant for: Miltenyi Biotec
Planner/Presenter
Iskra Pusic, MD
Associate Professor
Washington University St. Louis
St. Louis, MO
Iskra Pusic, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant for: Incyte
The following relationships have ended within the last 24 months:
Advisory Board/Consultant for: Syndax
All of the relevant financial relationships of individuals for this activity have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and Aplastic Anemia and MDS International Foundation, the joint provider, do not have any relevant financial relationships to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. You will receive your certificate from Medical Learning Institute, Inc. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board. If you have questions regarding your certificate, please contact Mary Vu via email at mvu@mlieducation.org
About this Activity
Medical Learning Institute, Inc. and Aplastic Anemia and MDS International Foundation are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.
Copyright © 2022 Medical Learning Institute, Inc. All Rights Reserved.